Poster Presentation Asia Pacific Stroke Conference 2024

Background/aims:

The risk of ischemic stroke is greatest in the first 90 days after a minor ischemic stroke or TIA. We conducted a retrospective audit to identify if patients on antithrombotic therapy for ischemic stroke or TIA received enoxaparin and any associated adverse events. The purpose of this study is to look at outcomes in terms of thromboembolic and bleeding events. The results of this audit could inform clinicians regarding appropriate venous thromboembolism prophylaxis choice in TIA and ischemic stroke inpatients.

Methods:

• We conducted a retrospective audit of patients admitted to our health service between 01/01/21 to 31/12/22, aged 18 and above, with a confirmed diagnosis of ischemic stroke or TIA and treated with antiplatelet/anticoagulation therapy for a minimum of 21 days.
• Electronic medical records were accessed manually to collect stroke type, treatment type and duration, and adverse events for patients commenced on therapy.

Results:

A total of 270 patients on antithrombotic therapy with or without enoxaparin were audited, with 9 recorded major bleeding events and 1 recorded thromboembolic event. There was no significant difference in the number of major bleeding events between groups of patients on single antiplatelet therapy, dual antiplatelet therapy, or oral anticoagulation, with or without enoxaparin.

Conclusion:

• Our preliminary results have identified that among patients on different antithrombotic therapies, there was no significant difference in the number of adverse events in those on enoxaparin compared with those without.